Skip to main content

Grifols Value Stock - Dividend - Research Selection

Grifols SA

ISIN: ES0171996087, WKN: A2ABUQ

Market price date: 20.07.2021
Market price: 12,98 EUR




Grifols SA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 16-06-2021
Cash flow
Net operating cash flow 1.110.340.000
Capital Expenditures -362.560.000
Free cash flow 747.779.968
Balance sheet
Total Equity 5.108.390.000
Liabilities & Shareholders equity 15.274.800.000
Income statement
Net income 708.990.000
Eps (diluted) 0,900
Diluted shares outstanding 684.543.000
Net sales/revenue 5.340.040.000

Fundamental ratios calculated on: 20-07-2021

Ratios
Key figures 20-07-2021
Cash flow
P/C 8,00
   
P/FC 11,88
Balance sheet
ROI4,64
ROE33,44
Income statement
P/E14,42
Div. Yield0,00%
P/B1,74
P/S1,66


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolGRF-P.MC
Market Capitalization10.776.674.304,00 USD
Country
IndicesIBEX 35
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split2016-01-05,2.0000/1.0000; 2016-01-04,2.0000/1.0000; 2012-12-11,2.0000/1.0000
Internetwww.grifols.com


Description of the company

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.grifols.com